These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24845362)

  • 1. Heart failure: the role for mineralocorticoid receptor antagonists.
    Pitt B
    Swiss Med Wkly; 2014; 144():w13959. PubMed ID: 24845362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
    Talatinian A; Chow SL; Heywood JT
    Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
    Pitt B; Rossignol P
    Expert Opin Drug Saf; 2016 May; 15(5):659-65. PubMed ID: 26958701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
    Oh J; Kang SM; Song MK; Hong N; Youn JC; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Chae SC; Oh BH; Choi DJ; Lee MM; Ryu KH
    Am Heart J; 2015 May; 169(5):713-720.e3. PubMed ID: 25965719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
    Teerlink JR; Massie BM;
    J Card Fail; 2003 Jun; 9(3):158-63. PubMed ID: 12815564
    [No Abstract]   [Full Text] [Related]  

  • 13. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 15. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving strategies for the use of spironolactone in cardiovascular disease.
    Jolobe OM
    Eur J Intern Med; 2013 Jun; 24(4):303-9. PubMed ID: 23245930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
    Heggermont WA; Goethals M; Dierckx R; Verstreken S; Bartunek J; Vanderheyden M
    Heart Fail Rev; 2016 Nov; 21(6):699-701. PubMed ID: 27620301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
    Zannad F; Gattis Stough W; Rossignol P; Bauersachs J; McMurray JJ; Swedberg K; Struthers AD; Voors AA; Ruilope LM; Bakris GL; O'Connor CM; Gheorghiade M; Mentz RJ; Cohen-Solal A; Maggioni AP; Beygui F; Filippatos GS; Massy ZA; Pathak A; Piña IL; Sabbah HN; Sica DA; Tavazzi L; Pitt B
    Eur Heart J; 2012 Nov; 33(22):2782-95. PubMed ID: 22942339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.